Plasma Soluble C-type Lectin-like Receptor-2 is Associated with the Risk of Coronary Artery Disease

Overview

Journal Front Med

Specialty General Medicine

Date 2019 Jul 8

PMID 31280468

Citations 14

Authors

Min Fei

Li Xiang

Xichen Chai

JingChun Jin

Tao You

Yiming Zhao

Changgeng Ruan

Yiwen Hao

Li Zhu

Affiliations

Soon will be listed here.

Abstract

Accumulating evidence suggests that C-type lectin-like receptor-2 (CLEC-2) plays an important role in atherothrombosis. In this case-control study, we investigated the association between CLEC-2 and incidence of coronary artery disease (CAD). A total of 216 patients, including 14 cases of stable angina pectoris (SAP, non-ACS) and 202 cases of acute coronary syndrome (ACS), and 89 non-CAD control subjects were enrolled. Plasma levels of soluble CLEC-2 (sCLEC-2) were measured using the enzyme-linked immunosorbent assay (ELISA). Compared with the control group (65.69 (55.36-143.22) pg/mL), the plasma levels of sCLEC-2 were significantly increased in patients with CAD (133.67 (88.76-220.09) pg/mL) and ACS (134.16 (88.88-225.81) pg/mL). The multivariate adjusted odds ratios (95% confidence interval) of CAD reached 2.01 (1.52-2.66) (P < 0.001) for each 1-quartile increase in sCLEC-2. Restricted cubic splines showed a positive dose-response association between sCLEC2 and CAD incidence (P < 0.001). The addition of sCLEC-2 to conventional risk factors improved the C statistic (0.821 vs. 0.761, P = 0.004) and reclassification ability (net reclassification improvement: 57.45%, P < 0.001; integrated discrimination improvement: 8.27%, P < 0.001) for CAD. In conclusion, high plasma sCLEC-2 is independently associated with CAD risk, and the prognostic value of sCLEC-2 may be evaluated in future prospective studies.

Citing Articles

The Dectin-1 and Dectin-2 clusters: C-type lectin receptors with fundamental roles in immunity.

Malamud M, Brown G EMBO Rep. 2024; 25(12):5239-5264.

PMID: 39482490 PMC: 11624271. DOI: 10.1038/s44319-024-00296-2.

Detection of Thrombosis Using Soluble C-Type Lectin-like Receptor-2 with D-Dimer Level and Platelet Count.

Wada H, Shiraki K, Yamamoto A, Kamon T, Masuda J, Ichikawa Y J Clin Med. 2024; 13(19).

PMID: 39408040 PMC: 11477887. DOI: 10.3390/jcm13195980.

C-type lectin-like receptor 2: roles and drug target.

Sun L, Wang Z, Liu Z, Mu G, Cui Y, Xiang Q Thromb J. 2024; 22(1):27.

PMID: 38504248 PMC: 10949654. DOI: 10.1186/s12959-024-00594-8.

Super Formula for Soluble C-Type Lectin-Like Receptor 2 × D-Dimer in Patients With Acute Cerebral Infarction.

Kamon T, Wada H, Horie S, Inaba T, Okamoto K, Shiraki K Clin Appl Thromb Hemost. 2024; 30:10760296241232858.

PMID: 38403943 PMC: 10896059. DOI: 10.1177/10760296241232858.

C-Type Lectin-like Receptor 2 Expression Is Decreased upon Platelet Activation and Is Lower in Most Tumor Entities Compared to Healthy Controls.

Etemad M, Christodoulou F, Uhlig S, Hassel J, Schrotz-King P, Brenner H Cancers (Basel). 2023; 15(23).

PMID: 38067218 PMC: 10705117. DOI: 10.3390/cancers15235514.

References

Hu F, Willett W . Optimal diets for prevention of coronary heart disease. JAMA. 2002; 288(20):2569-78. DOI: 10.1001/jama.288.20.2569. View

Inoue O, Hokamura K, Shirai T, Osada M, Tsukiji N, Hatakeyama K . Vascular Smooth Muscle Cells Stimulate Platelets and Facilitate Thrombus Formation through Platelet CLEC-2: Implications in Atherothrombosis. PLoS One. 2015; 10(9):e0139357. PMC: 4587843. DOI: 10.1371/journal.pone.0139357. View

Furman M, Benoit S, Barnard M, Valeri C, Borbone M, Becker R . Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol. 1998; 31(2):352-8. DOI: 10.1016/s0735-1097(97)00510-x. View

Fox K, Anderson Jr F, Dabbous O, Steg P, Lopez-Sendon J, Van de Werf F . Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE). Heart. 2006; 93(2):177-82. PMC: 1861403. DOI: 10.1136/hrt.2005.084830. View

Suzuki-Inoue K, Osada M, Ozaki Y . Physiologic and pathophysiologic roles of interaction between C-type lectin-like receptor 2 and podoplanin: partners from in utero to adulthood. J Thromb Haemost. 2016; 15(2):219-229. DOI: 10.1111/jth.13590. View

Amsterdam E, Wenger N, Brindis R, Casey Jr D, Ganiats T, Holmes Jr D . 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 130(25):2354-94. DOI: 10.1161/CIR.0000000000000133. View

Shechter M, Merz C, Shah P, Kaul S . Plasma apolipoprotein B levels predict platelet-dependent thrombosis in patients with coronary artery disease. Cardiology. 2000; 92(3):151-5. DOI: 10.1159/000006964. View

Muller K, Chatterjee M, Rath D, Geisler T . Platelets, inflammation and anti-inflammatory effects of antiplatelet drugs in ACS and CAD. Thromb Haemost. 2015; 114(3):498-518. DOI: 10.1160/TH14-11-0947. View

Naghavi M, Libby P, Falk E, Casscells S, Litovsky S, Rumberger J . From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation. 2003; 108(15):1772-8. DOI: 10.1161/01.CIR.0000087481.55887.C9. View

10.

Suzuki-Inoue K . CLEC-2/podoplanin and thromboinflammation. Blood. 2017; 129(14):1896-1898. DOI: 10.1182/blood-2017-02-764670. View

11.

Strauss W, Cella G, Parisi A, SASAHARA A . Serial studies of platelet factor 4 and beta thromboglobulin during exercise in patients with coronary artery disease. Am Heart J. 1985; 110(2):293-9. DOI: 10.1016/0002-8703(85)90147-4. View

12.

Weber C, Noels H . Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011; 17(11):1410-22. DOI: 10.1038/nm.2538. View

13.

George R, Bhatt A, Narayani J, Thulaseedharan J, Sivadasanpillai H, Tharakan J . Enhanced P-selectin expression on platelet-a marker of platelet activation, in young patients with angiographically proven coronary artery disease. Mol Cell Biochem. 2016; 419(1-2):125-33. DOI: 10.1007/s11010-016-2756-4. View

14.

Anvari M, Boroumand M, Karimi A, Alidoosti M, Yazdanifard P, Shirzad M . Aortic and mitral valve atherosclerosis: Predictive factors and associations with coronary atherosclerosis using Gensini score. Arch Med Res. 2009; 40(2):124-7. DOI: 10.1016/j.arcmed.2008.12.003. View

15.

Rath D, Chatterjee M, Borst O, Muller K, Langer H, Mack A . Platelet surface expression of stromal cell-derived factor-1 receptors CXCR4 and CXCR7 is associated with clinical outcomes in patients with coronary artery disease. J Thromb Haemost. 2015; 13(5):719-28. DOI: 10.1111/jth.12870. View

16.

Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C . Circulating microRNAs in patients with coronary artery disease. Circ Res. 2010; 107(5):677-84. DOI: 10.1161/CIRCRESAHA.109.215566. View

17.

Kazama F, Nakamura J, Osada M, Inoue O, Oosawa M, Tamura S . Measurement of soluble C-type lectin-like receptor 2 in human plasma. Platelets. 2015; 26(8):711-9. DOI: 10.3109/09537104.2015.1021319. View

18.

Gimenez M, Twerenbold R, Mueller C . Beyond cardiac troponin: recent advances in the development of alternative biomarkers for cardiovascular disease. Expert Rev Mol Diagn. 2015; 15(4):547-56. DOI: 10.1586/14737159.2015.1010519. View

19.

Gorog D . Prognostic value of plasma fibrinolysis activation markers in cardiovascular disease. J Am Coll Cardiol. 2010; 55(24):2701-9. DOI: 10.1016/j.jacc.2009.11.095. View

20.

May F, Hagedorn I, Pleines I, Bender M, Vogtle T, Eble J . CLEC-2 is an essential platelet-activating receptor in hemostasis and thrombosis. Blood. 2009; 114(16):3464-72. DOI: 10.1182/blood-2009-05-222273. View